Integrated Filing — IndAS



General information about company

Scrip Code 544866
NSE Symbol MOLBIO
MSEI Symbol NOTLISTED
ISIN INE869T01028
Name of company Molbio Diagnostics Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 02-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Half yearly
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 05-11-2026   15:36:00
End date and time of board meeting 05-11-2026   16:03:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 66,739.60 66,739.60
Other income 887.40 887.40
Total income 67,627.00 67,627.00
2 Expenses
(a) Cost of materials consumed 24,446.60 24,446.60
(b) Purchases of stock-in-trade 973.50 973.50
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (512.10) (512.10)
(d) Employee benefit expense 8,371.70 8,371.70
(e) Finance costs 1,955.70 1,955.70
(f) Depreciation, depletion and amortisation expense 4,043.30 4,043.30
(f) Other Expenses
1 Other expenses 19,006.80 19,006.80
Total other expenses 19,006.80 19,006.80
Total expenses 58,285.50 58,285.50
3 Total profit before exceptional items and tax 9,341.50 9,341.50
4 Exceptional items 0.00 0.00
5 Total profit before tax 9,341.50 9,341.50
6 Tax expense
7 Current tax 3,576.70 3,576.70
8 Deferred tax (279.80) (279.80)
9 Total tax expenses 3,296.90 3,296.90
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,044.60 6,044.60
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (0.10) (0.10)
16 Total profit (loss) for period 6,044.50 6,044.50
17 Other comprehensive income net of taxes 353.60 353.60
18 Total Comprehensive Income for the period 6,398.10 6,398.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 7,386.90 7,386.90
Total profit or loss, attributable to non-controlling interests (1,342.40) (1,342.40)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 218.80 218.80
Total comprehensive income for the period attributable to owners of parent non-controlling interests 134.84 134.84
21 Details of equity share capital
Paid-up equity share capital 1,152.40 1,152.40
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 6.52 6.52
Diluted earnings (loss) per share from continuing operations 6.51 6.51
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 6.52 6.52
Diluted earnings (loss) per share from continuing and discontinued operations 6.51 6.51
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The Statement of unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026,of Molbio Diagnostics Limited ( the Holding Company or the Company), its subsidiaries and associate (together hereinafter referred to as the Group) have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company in their meeting held on November 05, 2026. The statutory auditors have conducted a limited review of the above unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026. 2. The Statement of unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of the Group has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 3. During the quarter and six months ended September 30, 2026, the Holding Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of Rs. 1 each at an issue price of Rs. 807 per equity share to investors and at an issue price of Rs. 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to Rs. 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to Rs. 7,396.96 Million. The Holding Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026. Further, out of the total proceeds of Rs. 2,000.00 Million raised through the fresh issue pursuant to IPO, the Holding Company is in the process of utilisation of the proceeds towards the objects of the Offer as disclosed in the offer document and the unutilised proceeds are temporarily invested in fixed deposit and other bank balances. 4. The shareholders of the Holding Company through a special resolution approved the ‘Employee Stock Option Plan 2025 (ESOP 2025/ Plan) for creation of ESOP pool of 2,819,000 options having face value of Rs. 1 each. During the quarter and six months ended September 30, 2026, the Holding Company granted 854,480 options to the employees of the Group, of which 5,656 options have been forfeited. 5. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the New Labour Codes. The Group had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by Rs. 35.08 Million and increase in leave liability (compensated absences) by Rs. 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Group continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules thereto. 6. A survey under Section 133A of the Income-tax Act, 1961 (IT Act), was carried out at the premises of the Holding Company and Bigtec Private Limited, a subsidiary, by the Income Tax authorities during the year ended March, 2024 followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Holding Company. The department has raised tax demands aggregating to Rs. 208.71 Million plus interest and penalty, as applicable on the Holding Company, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Holding Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications. Management believes that the Group has complied with all the applicable provisions of the IT Act with respect to its operations. The Holding Company has paid an amount of Rs. 78.95 Million as at September 30, 2026 under protest in connection with the survey. The management of the Group is confident of favourable outcome and accordingly no adjustments have been made in the unaudited consolidated financial results for the quarter and six months ended September 30, 2026 in this regard. 7. a. During the year ended March 31, 2025, the Holding Company, OptraSCAN, Inc. (OptraSCAN), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Holding Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of Rs. 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Holding Company. Further, during the year ended March 31, 2026, the Holding Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of Rs. 2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Holding Company's shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Holding Company. Pursuant to this acquisition, the Group had derecognised its investment in associate as it now holds 60% interest and have gained control as a subsidiary. Accordingly share of loss amounting to Rs. 38.42 million has been recognised as gain on remeasurement of previously held interest in associate and has been disclosed as an exceptional item for the year ended March 31, 2026. b. As at March 31, 2026, the Holding Company held a stake of 65.47% in Prognosys Medical Systems Private Limited (PMS). During the quarter ended June 30, 2026, the Holding Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Holding Company’s cumulative shareholding in PMS increased from 65.47% to 70.00%. 8. The operating segment of the Group is identified to be “manufacturing of diagnostic devices, chips, reagents, etc” and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 “Operating segments” and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Group. 9. During the quarter ended September 30, 2025, the Holding Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Companies Act, 2013 in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of Rs. 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended September 30, 2025 and six months ended September 30, 2025 have been adjusted restrospectively and presented accordingly. 10. Unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026, includes the unaudited financial results of subsidiaries Bigtec Private Limited, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited, OptraSCAN Inc. w.e.f. November 01, 2025 (associate till October 31, 2025), OptraScan India Private Limited w.e.f. November 01, 2025 (associate till October 31, 2025) and associate Chayagraphics (India) Private Limited. 11. The financial results for the quarter ended September 30, 2025 represent the balancing figures between the unaudited financial results for the six months ended September 30, 2025 and the unaudited financial results for the quarter ended June 30, 2025, both of which were compiled by management. Neither the financial results for the quarter ended September 30, 2025 and six months ended September 30, 2025 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 24,332.80
Capital work-in-progress 1,755.40
Investment property
Goodwill 6,212.80
Other intangible assets 15,975.10
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method 597.60
Non-current financial assets
Non-current investments 0.30
Trade receivables, non-current
Loans, non-current 0.00
Other non-current financial assets
1 Non-current financial assets 5,559.00
Total of other non-current financial assets 5,559.00
Total non-current financial assets 5,559.30
Deferred tax assets (net) 5,259.30
Other non-current assets
1 Non-current tax assets (net) 2,995.30
2 Other non-current assets 5,771.60
3 Right-of-use assets 5,498.40
Total of other non-current assets 14,265.30
Total non-current assets 73,957.60
2 Current assets
Inventories 45,626.30
Current financial asset
Current investments 0.00
Trade receivables, current 30,232.90
Cash and cash equivalents 49,312.80
Bank balance other than cash and cash equivalents 7,612.60
Loans, current 0.00
Other current financial assets
Total of other current financial assets 8,332.70
Total current financial assets 95,491.00
Current tax assets (net)
Other current assets
1 Other current assets 17,793.90
Total of other current assets 17,793.90
Total current assets 1,58,911.20
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 2,32,868.80
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,152.40
Other equity 1,42,892.00
Total equity attributable to owners of parent 1,44,044.40
Non controlling interest 12,682.90
Total equity 1,56,727.30
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 19,393.80
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 2,791.10
2 Net employee defined benefit liabilities 870.00
Total of other non-current financial liabilities 3,661.10
Total non-current financial liabilities 23,054.90
Provisions, non-current 0.00
Deferred tax liabilities (net) 3,138.60
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 26,193.50
Current liabilities
Current financial liabilities
Borrowings, current 15,768.40
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,979.20
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 11,967.30
Total Trade payable 14,946.50
Other current financial liabilities
1 Current financial liabilities 2,996.90
2 Lease liabilities 1,027.90
Total of other current financial liabilities 4,024.80
Total current financial liabilities 34,739.70
Other current liabilities 11,899.80
1 Net employee defined benefit liabilities 250.20
2 Other current liabilities 11,649.60
Total of other current liabilities 11,899.80
Provisions, current 3,308.50
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 49,948.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 76,141.50
Total equity and liabilites 2,32,868.80
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 (i) Re-measurement gains / (losses) on defined benefit plan 29.30 29.30
Total Amount of items that will not be reclassified to profit and loss 29.30
2 Income tax relating to items that will not be reclassified to profit or loss 3.00 3.00
3 Amount of items that will be reclassified to profit and loss
1 (i) Exchange gain / (loss) on translating the financial statements of foreign operations 327.30 327.30
Total Amount of items that will be reclassified to profit and loss 327.30
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 353.60 353.60



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,871.50
Adjustments for decrease (increase) in inventories (1,312.10)
Adjustments for decrease (increase) in trade receivables, current 10,784.10
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,657.80)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,244.70)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4,043.30
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss (177.70)
Adjustments for provisions, current 619.30
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (135.30)
Adjustments for dividend income 0.00
Adjustments for interest income 717.50
Adjustments for share-based payments 198.20
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (18.40)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 12,252.90
Net cash flows from (used in) operations 21,594.40
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,882.30
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 16,712.10
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 3.80
Purchase of property, plant and equipment 3,357.20
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 691.40
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (11,433.40)
Net cash flows from (used in) investing activities (14,095.40)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 20,000.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 731.90
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,038.00
Repayments of borrowings 9,016.30
Payments of lease liabilities 643.40
Dividends paid 0.00
Interest paid 1,683.50
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 8,962.90
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 11,579.60
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 307.30
Net increase (decrease) in cash and cash equivalents 11,886.90
Cash and cash equivalents cash flow statement at beginning of period 33,577.30
Cash and cash equivalents cash flow statement at end of period 45,464.20